Sep 2022

Bioscience Seminar

New Therapies in Cancer from Epigenetic Drugs to CAR-T cells

Professor Felipe Luis Prósper Cardoso
29 Sep, 2022
03:00 PM – 04:00 PM

Host: Professor David Gomez-Cabrero

In the current seminar, I will discuss some of the work that has been performed in my laboratory during the last few years, covering the role of epigenetics in the development and treatment of cancer. The indisputable role of epigenetics in cancer and the fact that epigenetic alterations can be reversed have favoured development of epigenetic drugs. In our lab, we designed and synthesize potent novel, selective and reversible chemical probes that simultaneously inhibit the G9a and DNMTs methyltransferase activity named CM-272. During the last few years we have explored the efficacy of CM-272 in hematological as well as solid tumors and have demonstrated its potential both in vitro and in vivo models of acute myeloblastic and lymphoblastic leukemia, but also hepato and cholangiocarcinoma. The demonstration of the potential mechanism of action has led to the combination of CM-272 with checkpoint inhibitors and Bcl-2 demonstrating a remarkable activity in in vivo models of metastatic bladder carcinoma.

Undoubtedly, CAR-T cells have revolutionized treatment of hematological malignancies, specifically B-cell tumors such as ALL, NHL and myeloma. In my lab we initiated a translational program of CAR-T cells focus on the development of academic CAR-T cells and the identification of new strategies aiming to improve the clinical results, including the development of CAR-T cells for solid tumors. I will present some of our recent results with an academic BCMA CAR-T for multiple myeloma, the identification of a new CAR-T directed against the tumor microenvironment of solid tumors and the demonstration of the impact of the level of expression of the CAR in their efficacy.

Professor Prosper graduated from the University of Navarra in 1989 and after his residency and PhD (1994), he completed a fellowship and postdoctoral training at the University of Minnesota. Relocated to the Clinica Universidad de Navarra in 2001, he was responsible for the development of the Cell Therapy program, becoming the Head of the Hematology Department in 2003. In 2012, Professor Prosper was appointed as the Director of the programs of Hematology-Oncology and Regenerative Medicine at CIMA Universidad de Navarra. Professor Prosper ́s principal research interest and key discoveries have been focused on two main research areas: ¨Molecular bases of the hematological malignancies¨ and ¨Application of Cell Therapy and Regenerative Medicine in the field of human diseases¨.

Google scholar: https://scholar.google.com/citations?user=nrsUgKoAAAAJ&hl=en&oi=ao

Event Quick Information

29 Sep, 2022
03:00 PM - 04:00 PM
Auditorium between Buildings 4 & 5